USPTO Patent Applications - Therapeutics (A61P)

Patent Application for Cancer Treatment Combination Therapies

The USPTO has published a new patent application (US20260083816A1) detailing methods for treating cancer using combination therapies. The application, filed by inventors Erlinda M. Gordon and Fredrick L. Hall, focuses on inhibiting cyclin proteins and targeting pathways that promote cyclin activity.

USPTO Patent Application for Dietary Supplement Formulation

The USPTO has published a patent application (US20260083814A1) for a dietary supplement formulation designed to alleviate sciatica pain and support nerve and musculoskeletal health. The application details a specific blend of natural ingredients and their purported benefits, filed on September 26, 2024.

Patent Application for Reducing DPP-4 Activity with Plants

The USPTO has published a new patent application (US20260083813A1) detailing methods and compositions using plants like Dichrostachys glomerata or Cissus quadrangularis to reduce DPP-4 activity or levels in mammals. The application was filed on September 26, 2024.

Patent Application: Reducing Fasting Blood Glucose Using Plants

The USPTO has published a new patent application detailing methods and compositions for reducing fasting blood glucose using plants like Dichrostachys glomerata or Cissus quadrangularis. The application, filed on September 26, 2024, describes oral dosage forms for health benefits including increased GLP-1 levels and reduced blood lipids.

Patent Application: Reducing Blood Lipids Using Plants

The USPTO has published a patent application (US20260083811A1) detailing methods and compositions for reducing blood lipids using plants like Dichrostachys glomerata or Cissus quadrangularis. The application, filed on September 26, 2024, describes compositions aimed at increasing GLP-1 levels and reducing visceral fat, food intake, blood lipids, total cholesterol, and total glucose.

Patent Application: Reducing Visceral Fat Using Plants and Spices

The USPTO has published a new patent application (US20260083810A1) detailing methods and compositions for reducing visceral fat in mammals using plants and spices such as Dichrostachys glomerata or Cissus quadrangularis. The application was filed on September 26, 2024, and is scheduled for publication on March 26, 2026.

Patent Application: Reducing Food Intake Using Plants

The USPTO has published a new patent application (US20260083809A1) detailing methods and compositions using plants like Dichrostachys glomerata or Cissus quadrangularis to reduce food intake or appetite in mammals. The application was filed on September 26, 2024, and is expected to be published on March 26, 2026.

Antiviral Fungal Extracts Prevent Coronavirus Infections

The USPTO has published a patent application (US20260083788A1) detailing antiviral fungal extracts that may prevent coronavirus infections by interfering with the Spike protein. The application, filed by Mycotech Pharma AS, describes compositions derived from Agaricus blazei, Grifola frondosa, and Hericium erinaceus.

US Patent Application for Heart Boosting Formulation

The USPTO has published a new patent application (US20260083806A1) for a heart boosting formulation. The application details a specific composition including L-carnitine, alpha-linolenic acid, citrulline, vitamin D3, lycopene, holy basil, cinnamon, and beetroot, along with related manufacturing methods. The filing date was September 16, 2025.

Patent Application for Dichrostachys glomerata to Reduce Anxiety and Improve Mood

The USPTO has published a patent application (US20260083797A1) detailing methods and compositions using Dichrostachys glomerata to reduce anxiety, food cravings, and stress, and to improve mood, energy, and overall health in mammals. The application was filed on September 26, 2024.

Patent Application for Dichrostachys glomerata to Reduce Anxiety and Stress

The USPTO has published a new patent application (US20260083796A1) detailing methods and compositions using Dichrostachys glomerata to reduce anxiety, stress, and food cravings, while improving mood and overall health in mammals. The application was filed on September 26, 2024, by inventor Shil Kothari.

Patent Application for Dichrostachys glomerata Health Benefits

The USPTO has published a patent application (US20260083794A1) detailing methods and compositions using Dichrostachys glomerata for various health benefits, including reducing anxiety and improving mood. The application was filed on September 26, 2024, and is expected to be published on March 26, 2026.

Patent Application: Dichrostachys glomerata for Anxiety and Stress Reduction

The USPTO has published a patent application (US20260083793A1) detailing methods and compositions using Dichrostachys glomerata to reduce anxiety, stress, and food cravings, while improving mood and energy. The application was filed on September 25, 2024, by inventor Shil Kothari.

Patent Application for Dichrostachys glomerata to Reduce Anxiety and Cravings

The USPTO has published a new patent application (US20260083792A1) for methods and compositions using Dichrostachys glomerata to reduce anxiety, stress, food cravings, and improve mood and overall health. The application was filed on September 25, 2024, by inventor Shil Kothari.

Patent Application: Dichrostachys glomerata Health Benefits

The USPTO has published a patent application (US20260083791A1) detailing methods and compositions using Dichrostachys glomerata for various health benefits, including reducing anxiety, food cravings, and stress, and improving mood and energy. The application was filed on September 25, 2024, by inventor Shil Kothari.

Formulation for Hair Growth

The USPTO has published a new patent application, US20260083789A1, for a formulation designed to stimulate hair growth and improve hair quality. The formulation primarily utilizes a nitrate-enriched extract of Amaranth, along with other plant-based ingredients. The application details the method of preparation and its potential use in enhancing hair growth rate, count, and density.

GABA-producing bacteria for improving health patent application

The USPTO has published a new patent application (US20260083786A1) detailing a composition comprising Lactobacillus brevis (NCIMB 41903) for use in regulating or treating metabolic diseases. The application was filed on September 17, 2025, by inventors Paul Ross and Catherine Stanton.

Patent Application: Bifidobacterium longum for Infant Infection Prevention

The USPTO has published a patent application (US20260083785A1) detailing the use of Bifidobacterium longum transitional microorganisms to prevent or reduce the risk of infection in infants and young children. The application was filed on September 27, 2023.

Adjuvant Composition with STING Agonist and Aluminium Hydroxide

The USPTO has published a patent application by GlaxoSmithKline Biologicals SA for an adjuvant composition comprising a STING agonist and an aluminum-based adjuvant. The application details immunogenic compositions and their use in immunizing subjects.

Meloxicam Pharmaceutical Composition and Application

The USPTO has published a patent application (US20260083748A1) for a pharmaceutical composition containing meloxicam, a composite solvent, and an acidic pH regulator. The assignee is Beijing Tide Pharmaceutical Co., Ltd. This application details a preparation method and its application, focusing on a formulation that avoids organic solvents for increased safety and reduced environmental impact.

Patent Application: T-cell receptors target mutant RAS for cancer treatment

The USPTO has published patent application US20260083847A1 concerning T-cell receptors and compositions for treating cancer associated with mutant RAS. The application details methods and compositions involving T-cell receptors that bind to specific mutant RAS peptide fragments in the context of specific HLA types.

Antimicrobial Compositions Patent Application

The USPTO has published a patent application (US20260083126A1) for antimicrobial compositions containing organosulfur compounds. The application, filed on September 8, 2023, describes compounds useful for treating microbial infections and for cleaning, disinfecting, or agricultural use.

Modified T-Cells for Bladder Cancer Treatment Application

The USPTO has published a patent application (US20260083849A1) detailing a method for treating bladder cancer using modified immunoresponsive cells. The application was filed on September 7, 2023, and is related to therapeutic applications in oncology.

CAR T-cell therapy combined with BTK inhibitors for cancer

The USPTO has published a new patent application (US20260083848A1) detailing a combination therapy for cancer treatment. The application describes the use of CAR T-cell therapy with BTK inhibitors for treating hematological malignancies. This represents a new disclosure in the field of cancer therapeutics.

Chemical Compound with Triazine Group and Production Method

The USPTO has published a patent application (US20260085087A1) for a chemical compound comprising a triazine group and its production method. The application relates to novel nucleotides and oligonucleotides with modified phosphate groups, potentially useful in diagnostics, gene therapy, and treating bacterial and viral diseases, including COVID-19.

USPTO Patent for Therapeutic Compounds Treating Cancer

The USPTO has published patent application US20260085059A1 for therapeutic compounds and methods of use in treating cancer. The patent was assigned to Servier Pharmaceuticals LLC and lists Samuel V. Agresta et al. as inventors. The application was filed on May 7, 2025.

Proteoglycan Mimetics for Wound Healing and Angiogenesis

The USPTO has published a new patent application, US20260083852A1, detailing proteoglycan mimetics for enhanced wound healing and angiogenesis. The application describes compounds designed to support tissue regeneration and promote vascular repair, potentially limiting systemic exposure to VEGF activity.

Patent for Radiation Dose Enhancement and Tumor Delineation

The USPTO has published a new patent application (US20260083850A1) for compounds, compositions, and methods related to radiation dose enhancement and tumor delineation. The application, assigned to the University of Connecticut, focuses on using barium nanoparticles for improved radiation therapy and tumor identification.

USPTO Patent Application: Polynucleotides Targeting NR4A3

The USPTO has published a patent application (US20260083846A1) filed by Lyell Immunopharma, Inc. The application describes polynucleotides designed to target the NR4A3 gene and their potential use in treating diseases, including cancer. The patent is scheduled to be published on March 26, 2026.

Cellicure, Inc. Patent Application for Engineered Immune Cells

The USPTO has published a patent application (US20260083845A1) filed by Cellicure, Inc. on September 22, 2023. The application details engineered immune cells, specifically chimeric antigen receptors (CARs) for enhanced killing activities, primarily targeting cancer treatment.

Immune Cells Target EpCAM for Tumor Treatment

The USPTO has published a patent application (US20260083843A1) from SUZHOU IMMUNOHEAD BIOTECHNOLOGY CO., LTD. The application details the use of immune cells that target EpCAM for the prevention or treatment of metastatic tumors expressing EpCAM.

Patent Application: Vaccine for Bordetella pertussis using antigen peptides

The USPTO has published a patent application (US20260083833A1) for a vaccine against Bordetella pertussis using antigen peptides. The application details a method for preventing infection by targeting specific peptides processed and presented by CD4+ T cells. This relates to ongoing research and development in vaccine technology.

Novel agent for Alzheimer's treatment using dynamin 1 peptide

The USPTO has published a new patent application (US20260083826A1) from the Okinawa Institute of Science and Technology School Corporation for a novel agent to treat Alzheimer's disease. The application describes a peptide corresponding to dynamin 1, potentially encapsulated in nanoparticles for improved brain delivery.

USPTO Patent Application for WNT-Related Cancer Vaccines

The USPTO has published a patent application (US20260083831A1) filed by Geneos Therapeutics, Inc. The application details compositions and methods for treating WNT-related cancers using nucleic acid sequences encoding tumor-specific antigens, potentially in combination with checkpoint inhibitors.

Patent Application for Biodegradable Particles Delivering Therapeutic Agents

The USPTO has published a new patent application (US20260083830A1) for biodegradable polymeric particles designed for the extended, controlled release of positively charged therapeutic agents at neutral pH. The application details microparticles and nanoparticles comprising an uncapped polymer matrix and a net positively charged therapeutic agent.

Patent Application for DNase Enzyme Therapy for Tumor Microenvironment Immunomodulation

The USPTO has published a patent application (US20260083827A1) filed by CLS THERAPEUTICS LIMITED for methods of immunomodulating the tumor microenvironment using DNase enzyme therapy. The application details methods involving the administration of DNase enzyme, alone or with other agents, to combat immunosuppressive tumor cell microenvironments.

Wound healing composition with amino acids and fish collagen

The USPTO has published a new patent application detailing a composition for promoting wound healing. The composition includes an amino acid mixture and fish collagen, with a method for its administration also described. This application was filed on September 20, 2024.

Ocular Insulin Delivery Enhanced by Prostaglandin Analogues Patent Application

The USPTO has published a patent application (US20260083822A1) for a novel ocular insulin delivery system. The invention utilizes prostaglandin analogues to enhance insulin permeability across ocular tissues, offering a non-invasive alternative to injections for therapeutic effects.

Patent Application: Autism Symptom Treatment via Neurotensin Receptor Activation

The USPTO has published a new patent application (US20260083820A1) from the New York Institute of Technology for methods and formulations to treat autism symptoms by activating neurotensin receptor 1 (NTSR1) without causing significant lethargy. The application was filed on October 3, 2025.

Cancer Treatment Using TTFields and Interferon Gamma Compositions

The USPTO has published a new patent application detailing compositions, systems, and methods for treating cancer using Tumor Treating Fields (TTFields) in combination with interferon gamma. The application, filed on September 18, 2025, outlines a method for reducing cancer cell viability and tumor volume.

Phytogenic Composition for Animal Skeletal Muscle Growth

The USPTO has published a patent application (US20260083805A1) detailing a phytogenic composition comprising Glycyrrhiza uralensis extract for promoting skeletal muscle growth in animals. This application outlines its use as a feed additive for agricultural applications.

Patent Application: Reducing DPP-4 Activity Using Plants

The USPTO has published a new patent application (US20260083804A1) detailing methods and compositions for reducing DPP-4 activity using plants like Dichrostachys glomerata or Cissus quadrangularis. The application, filed on September 26, 2024, aims to provide health benefits such as increased GLP-1 levels and reduced visceral fat.

Patent Application for Reducing Blood Glucose with Plants

The USPTO has published a new patent application (US20260083803A1) detailing methods and compositions for reducing fasting blood glucose in mammals using plants like Dichrostachys glomerata or Cissus quadrangularis. The application was filed on September 26, 2024, and is expected to be published on March 26, 2026.

Patent Application: Methods for Reducing Blood Lipids Using Plants and Spices

The USPTO has published a new patent application (US20260083802A1) detailing methods and compositions for reducing blood lipids using plants and spices, specifically Dichrostachys glomerata or Cissus quadrangularis. The application was filed on September 26, 2024.

Patent Application for Reducing Visceral Fat Using Plants

The USPTO has published a new patent application (US20260083801A1) detailing methods and compositions for reducing visceral fat in mammals using plants like Dichrostachys glomerata or Cissus quadrangularis. The application was filed on September 26, 2024, and is expected to be published on March 26, 2026.

Patent application for Dichrostachys glomerata health and wellness benefits

Patent application for Dichrostachys glomerata health and wellness benefits

Patent Application for Reducing Food Intake Using Plants

The USPTO has published a new patent application (US20260083800A1) detailing methods and compositions using Dichrostachys glomerata or Cissus quadrangularis to reduce food intake or appetite in mammals. The application was filed on September 26, 2024, by inventors Shil Kothari and Julius Enyoug Oben.

USPTO Patent Application for Anti-CD38 Antibodies

The USPTO has published a patent application (US20260078199A1) for anti-CD38 antibodies, therapeutics, and diagnostics. The application, filed on July 14, 2025, details methods for treating autoimmune diseases and diagnostic assays.

Carboxyalkyl Chitosan Patent Application

The USPTO has published a patent application (US20260078203A1) for a carboxyalkyl chitosan. The application details compositions, manufacturing processes, and therapeutic applications in areas such as rheumatology, ophthalmology, and dermatology. The filing date was November 26, 2025.

Anti-PTK7 Antibody Patent Application

The USPTO has published a patent application (US20260078201A1) for an anti-PTK7 antibody. The antibody is described as inhibiting angiogenesis, tumor growth, and cancer, with potential therapeutic applications for angiogenesis-related diseases and PTK7-positive cancers.